A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata-Reference-Cited by-同舟云学术

A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata

Published:2018-11-11 Issue:1 Volume:311 Page:29-36
ISSN:0340-3696
Container-title:Archives of Dermatological Research
language:en
Short-container-title:Arch Dermatol Res

Author:

Mikhaylov Daniela,Pavel Ana,Yao Christopher,Kimmel Grace,Nia John,Hashim Peter,Vekaria Anjali S.,Taliercio Mark,Singer Giselle,Karalekas Rachel,Baum Danielle,Mansouri Yasaman,Lebwohl Mark G.,Guttman-Yassky Emma

Funder

Celgene

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

http://link.springer.com/article/10.1007/s00403-018-1876-y/fulltext.html

Reference40 articles.

1. Acikgoz G, Caliskan E, Tunca M, Yeniay Y, Akar A (2014) The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutan Ocul Toxicol 33:247–252. https://doi.org/10.3109/15569527.2013.839997

2. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J (2010) Alopecia areata update: part II. Treatment. J Am Acad Dermatol 62:191–202. https://doi.org/10.1016/j.jaad.2009.10.031 quiz 203 – 194.

3. Bakry OA, El Shazly RM, Basha MA, Mostafa H (2014) Total serum immunoglobulin E in patients with alopecia areata. Indian dermatology online journal 5:122–127. https://doi.org/10.4103/2229-5178.131076